title: Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer.
abstract: The treatment of advanced non-small cell lung cancer (NSCLC) may be changing, but the cisplatin-based doublet remains the foundation of treatment for the majority of patients with advanced NSCLC. In this respect, changes in practice to various aspects of cisplatin use, such as administration schedules and the choice of methods and frequency of monitoring for toxicities, have contributed to an incremental improvement in patient management and experience. Chemoresistance, however, limits the clinical utility of this drug in patients with advanced NSCLC. Better understanding of the molecular mechanisms of cisplatin resistance, identification of predictive markers and the development of newer, more effective and less toxic platinum agents is required. In addition to maximising potential benefits from advances in molecular biology and associated therapeutics, modification of existing cisplatin-based treatments can still lead to improvements in patient outcomes and experiences.
authors: Cancer Research UK Centre, University of Leicester & University Hospitals of Leicester, NHS Trust, Leicester, UK. Electronic address: df132@leicester.ac.uk.
authors: D A
authors: DA
authors: Fennell
authors: The Christie Hospital NHS Foundation Trust, 550 Wilmslow Road, Manchester M20 4BX, UK. Electronic address: Yvonne.Summers@christie.nhs.uk.
authors: Y
authors: Y
authors: Summers
authors: Chest Department and Expert Center in Thoracic Oncology, APHP Hôpital Tenon and Sorbonne Universités, UPMC Univ Paris 06, Paris, France. Electronic address: jacques.cadranel@aphp.fr.
authors: J
authors: J
authors: Cadranel
authors: St Georges Hospital NHS Trust, Blackshaw Road, Tooting, London SW17 0QT, UK. Electronic address: tim.benepal@stgeorges.nhs.uk.
authors: T
authors: T
authors: Benepal
authors: Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Hufelandstraße 55, D-45147, Essen, Germany. Electronic address: daniel.christoph@uk-essen.de.
authors: D C
authors: DC
authors: Christoph
authors: Guy's and St Thomas' Foundation Trust, Westminster Bridge Road, London SE1 7EH, UK. Electronic address: Rohit.Lal@gstt.nhs.uk.
authors: R
authors: R
authors: Lal
authors: Eli Lilly and Company, Lilly House, Priestley Road, Basingstoke, Hampshire RG24 9NL, UK. Electronic address: das_mayukh@lilly.com.
authors: M
authors: M
authors: Das
authors: Eli Lilly and Company, Lilly House, Priestley Road, Basingstoke, Hampshire RG24 9NL, UK. Electronic address: fiona_maxwell@lilly.com.
authors: F
authors: F
authors: Maxwell
authors: Eli Lilly and Company, Grootslag 1-5, 3991 RA Houten, The Netherlands. Electronic address: visseren-grul_carla@lilly.com.
authors: C
authors: C
authors: Visseren-Grul
authors: Eli Lilly and Company, Lilly House, Priestley Road, Basingstoke, Hampshire RG24 9NL, UK. Electronic address: ferry_david@lilly.com.
authors: D
authors: D
authors: Ferry
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage* / Q000266:history; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077143:Docetaxel; D055808:Drug Discovery / Q000266:history; D049672:History, 19th Century; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage; D043823:Taxoids / Q000008:administration & dosage; D000093542:Gemcitabine
chemical_list: D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D017239:Paclitaxel; D002945:Cisplatin; D000093542:Gemcitabine
keywords: Cisplatin; Doublet regimens; First-line; Non-small cell lung cancer